JP2024521224A5 - - Google Patents
Info
- Publication number
- JP2024521224A5 JP2024521224A5 JP2023575354A JP2023575354A JP2024521224A5 JP 2024521224 A5 JP2024521224 A5 JP 2024521224A5 JP 2023575354 A JP2023575354 A JP 2023575354A JP 2023575354 A JP2023575354 A JP 2023575354A JP 2024521224 A5 JP2024521224 A5 JP 2024521224A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- position corresponding
- complement
- notch3
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195970P | 2021-06-02 | 2021-06-02 | |
| US63/195,970 | 2021-06-02 | ||
| PCT/US2022/031756 WO2022256396A1 (en) | 2021-06-02 | 2022-06-01 | Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (notch3) agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521224A JP2024521224A (ja) | 2024-05-28 |
| JP2024521224A5 true JP2024521224A5 (https=) | 2025-05-22 |
Family
ID=82214220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575354A Pending JP2024521224A (ja) | 2021-06-02 | 2022-06-01 | 神経原性座位Ｎｏｔｃｈホモログタンパク質３（ＮＯＴＣＨ３）剤による脳血管疾患の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230000897A1 (https=) |
| EP (1) | EP4347634A1 (https=) |
| JP (1) | JP2024521224A (https=) |
| KR (1) | KR20240159455A (https=) |
| CN (1) | CN117396499A (https=) |
| AU (1) | AU2022285676A1 (https=) |
| CA (1) | CA3218042A1 (https=) |
| IL (1) | IL307903A (https=) |
| MX (1) | MX2023014341A (https=) |
| WO (1) | WO2022256396A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115820733B (zh) * | 2022-11-11 | 2024-12-17 | 北京希诺谷生物科技有限公司 | Cadasil疾病模型犬的建立方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751986B1 (fr) * | 1996-08-01 | 1998-12-31 | Inst Nat Sante Rech Med | Gene implique dans le cadasil, methode de diagnostic et application therapeutique |
| EP2389390B1 (en) * | 2009-01-26 | 2020-11-04 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| US11453718B2 (en) * | 2017-03-27 | 2022-09-27 | The Schepens Eye Research Institute, Inc. | NOTCH3 agonist compositions and methods for treating small vessel diseases |
| EP3449931B1 (en) * | 2017-08-28 | 2019-10-16 | EVER Neuro Pharma GmbH | Use of cerebrolysin |
| US20220168325A1 (en) * | 2019-03-25 | 2022-06-02 | The University Of Vermont | Methods to promote cerebral blood flow in the brain |
-
2022
- 2022-06-01 IL IL307903A patent/IL307903A/en unknown
- 2022-06-01 US US17/829,801 patent/US20230000897A1/en active Pending
- 2022-06-01 WO PCT/US2022/031756 patent/WO2022256396A1/en not_active Ceased
- 2022-06-01 CA CA3218042A patent/CA3218042A1/en active Pending
- 2022-06-01 JP JP2023575354A patent/JP2024521224A/ja active Pending
- 2022-06-01 KR KR1020237044937A patent/KR20240159455A/ko active Pending
- 2022-06-01 CN CN202280038673.9A patent/CN117396499A/zh active Pending
- 2022-06-01 AU AU2022285676A patent/AU2022285676A1/en active Pending
- 2022-06-01 EP EP22733821.7A patent/EP4347634A1/en active Pending
- 2022-06-01 MX MX2023014341A patent/MX2023014341A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pelisch et al. | CCL3 contributes to secondary damage after spinal cord injury | |
| Rosati et al. | NOTCH1 aberrations in chronic lymphocytic leukemia | |
| US20200237861A1 (en) | Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof | |
| WO2005056837A2 (en) | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof | |
| JP2009539960A (ja) | 加齢黄斑変性に対する保護および処置 | |
| JP2024521224A5 (https=) | ||
| Secchiero et al. | The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells | |
| JP2015523861A (ja) | 制御された遺伝子発現方法 | |
| US20230000897A1 (en) | Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents | |
| Bentley et al. | The apoptotic pathway: a target for therapy in chronic lymphocytic leukemia | |
| AU2022420000A1 (en) | Treatment of kidney diseases with angiopoietin like 3 (angptl3) inhibitors | |
| EP2227560B1 (en) | Methods for the treatment and diagnosis of bone mineral density related diseases | |
| Tesser-Gamba et al. | MAPK7 variants related to prognosis and chemotherapy response in osteosarcoma | |
| JP2024524374A5 (https=) | ||
| US7462447B2 (en) | Methods for evaluating susceptibility to a bone homeostasis disorder | |
| WO2010104588A2 (en) | Compositions and methods for characterizing and treating neoplasia | |
| Pace et al. | Precision Medicine for Sickle Cell Disease: Discovery of Genetic Targets for Drug Development | |
| JP2024524554A5 (https=) | ||
| US20240158795A1 (en) | Treatment Of Kidney Diseases With A Combination of Angiopoietin Like 3 (ANGPTL3) Inhibitors And Solute Carrier Family 5 Member 2 (SLC5A2) Inhibitors | |
| CN118488844A (zh) | 用淋巴细胞抗原75(ly75)、分化簇164(cd164)或聚(adp-核糖)聚合酶1(parp1)抑制剂治疗不确定潜能的克隆性造血(chip)的方法 | |
| JP2024524374A (ja) | 溶質輸送体ファミリー９アイソフォームａ３調節因子２（ｓｌｃ９ａ３ｒ２）阻害剤による高血圧症の治療 | |
| HK1194770A (en) | Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof |